Разработка подходов к созданию лекарственных форм антибиотиков на основе полимерных наночастиц
Диссертация
В частности, целесообразность применения ПАЦА для получения НФ обусловлена, прежде всего, их низкой токсичностью и биосовместимостью. Алкилцианоакрилаты, применяемые для получения этих НЧ, широко используют в медицине в качестве хирургических клеев, таких как Indennil® (2-п-бутилцианоакрилат, Henkel, Germany), Trufill® (2-п-бутилцианоакрилат, Cordis Neurovascular Inc., U. S), Dermabond… Читать ещё >
Список литературы
- Kreuter J. Nanoparticles. 1.: Swarbrick J., Boylan J.C. (Eds.), Encyclopedia of Pharmaceutical Technology. // M. Dekker. — New York. — 1994. — V.10. — P. 165−190.
- Швец В.И., Каплун А. П., Краснопольский Ю. М., Степанов А. Е., Чехонин В. П. От липосом семидесятых к нанобиотехнологии XXI века. // Рос. нанотехнол. 2008. — Т.З. — С.52−56.
- Дудниченко A.C., Краснопольский Ю. М., В.И. Швец. Липосомальные лекарственные препараты в эксперименте и клинике. // Харьков: РА-Каравелла. 2001. — 144 с.
- Kreuter J. Nanoparticles~a historical perspective. // Int J Pharm. 2007. -V.331, № 1. — P.1−10.
- Bala I., Hariharan S., Kumar M.N. PLGA nanoparticles in drug delivery: the state of the art. // Crit. Rev. Ther. Drug Carrier Syst. 2004. — V.21, No5. -P.387−422.
- Nguyen C.A., Konan-Kouakou Y.N., Allemann E., Doelker E., Quintanar-Guerrero D., Fessi H., Gurny R. Preparation of surfactant-free nanoparticles of methacrylic acid copolymers used for film coating. // AAPS PharmSciTech.- 2006. V.7, № 3. — Article 63.
- Vauthier C., Bouchemal K. Methods for the preparation and manufacture of polymeric nanoparticles. // Pharm. Res. 2008 — V.26, No5. -P.1025−1058
- Behan N., Birkinshaw C., Clarke N. Poly (n-butyl cyanoacrylate) nanoparticles: a mechanistic study of polymerisation and particle formation. // Biomaterials. -2001. V.22, Nol. -P.1335−1344.
- Pinto-Alphandary H., Andremont A., Couvreur P. Targeted delivery of antibiotics using liposomes and nanoparticles. Int. J. Antimicrob. Agents // -2000. V.13, No3. — P. 155−168.
- Moghimi S.M., Hunter A.C., Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. // Pharmacol. Rev. 2001. — V. 53, No2. -P. 283−318.
- Moghimi S.M., Hunter A.C. Capture of stealth nanoparticles by the body’s defences. // Crit. Rev. Ther. Drug Carrier Syst. 2001. — V. 18. — P.527−550.
- Moghimi S.M., Hunter A.C. Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. // Trends Biotechnol. 2000. — V. 18.- P.412−420.
- Araujo L., Loebenberg R., Kreuter J. Influence of the surfactant concentration on the body distribution of nanoparticles. // J. Drug Targeting. 1999. — V.6.- P.373−385.
- Redhead H.M., Davis S.S., Ilium L. Drug deliveiy in poly (lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: In vitro characterisation and in vivo evaluation. // J. Control. Release. 2001. — V.70. — P.353−363.
- Stolnik S., Ilium L., Davis S.S. Long circulating microparticle drug carriers. Adv. DrugDeliv. Rev. 1995. — V. l6. — P. 195−214.
- Moghimi S.M., Gray T. A single dose of intravenously injected poloxamine-coated long-circulating particles triggers macrophage clearance of subsequent doses in rats. // Clin. Sci. (Lond). 1997. — V. 93. — P.371−379.
- Peracchia M. T, Vauthier C., Passirani C., Couvreur P., Labarre D. Complement consumption by poly (ethylene glycol) in different conformations chemically coupled to poly (isobutyl 2-cyanoacrylate) nanoparticles. // Life Sci. 1997.- V.61.-P.749−761.
- Florence A.T., Hussain N. Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas. // Adv. Drug Deliv. Rev. 2001. — V.50. Suppl 1. — S69−89.
- Florence A.T. Issues in oral nanoparticle drug carrier uptake and targeting. // J. Drug Target. 2004. — V. 12. — P.65−70.
- Delie F., Blanco-Prfeto M.J. Polymeric particulates to improve oral bioavailability of peptide drugs. // Molecules. 2005. — V.10, Nol. — P.65−80.
- Sakuma S., Sudo R., Suzuki N., Kikuchi H., Akashi M., Ishida Y., Hayashi M. Behavior of mucoadhesive nanoparticles having hydrophilic polymeric chains in the intestine. // J. Control. Release. 2002. — V.81. — P.281−290.
- Yang S., Zhu J., Lu Y., Liang B., Yang C. Body distribution of camptothecin solid lipid nanoparticles after oral administration. // Pharm. Res. 1999. -V.16. — P.751−757.
- Ubrich N., Schmidt C., Bodmeier R., Hoffman M., Maincent P. Oral evaluation in rabbits of cyclosporin-loaded Eudragit RS or RL nanoparticles. // Int. J. Pharm. 2005. — V.288. — P. 169−175.
- Arbos P., Campanero M.A., Arangoa M.A., Irache J.M. Nanoparticles with specific bioadhesive properties to circumvent the pre-systemic degradation of fluorinated pyrimidines. // J. Control. Release. 2004. — V.96. — P.55−65.
- Moghimi S.M., Hawley A.E., Christy N.M., Gray T., Ilium L., Davis S.S. Surface engineered nanospheres with enhanced drainage into lymphatics and uptake by macrophages of the regional lymph nodes. // FEBS Lett. 1994. -V.344. -P.25−30.
- Moghimi S.M. Modulation of lymphatic distribution of subcutaneously injected poloxamer 407-coated nanospheres: the effect of the ethylene oxide chain configuration. // FEBS Lett. 2003. — V.540. — P.241−244.
- Jain R.K. Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function. // J. Control. Release. 2001. -V.74. — P. 7−25
- Padera T.P., Stoll B.R., Tooredman J.B., Capen D., di Tomaso E., Jain R.K. Cancer cells compress intratumour vessels. // Nature. 2004. — V.427. — P. 695.
- Maeda H., Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. // Crit. Rev. Ther. Drug Carrier Syst. 1989. — V.6. -P.193−210.
- Yi Y" Kim J.H., Kang H.W., Oh H.S., Kim S.W., Seo M.H. A polymeric nanoparticle consisting of mPEG-PLA-Toco and PLMA-COONa as a drug carrier: improvements in cellular uptake and biodistribution. // Pharm. Res. -2005. V.22. — P.200−208.
- Miura H., Onishi H., Sasatsu M., Machida Y. Antitumor characteristics of methoxypolyethylene glycol-poly (DL-lactic acid) nanoparticles containing camptothecin. // J. Control. Release. 2004. — V.97. — P. 101−113.
- Lenaerts V., Labib A., Chouinard F., Rousseau J., Ali H., van Lier J.E. Nanocapsules with a reduced liver uptake: targeting of phthalocyanines to EMT-6 mouse mammary tumor in vivo. // Eur. J. Pharm. Biopharm. 1995. -V.41. -P.38−43.
- Kaul G., Amiji M. Biodistribution and targeting potential of poly (ethylene glycol)-modified gelatin nanoparticles in subcutaneous murine tumor model. // Drug Target. 2004. — V.12. — P.585−591.
- Hobbs S.K., Monsky W.L., Yuan F., Roberts W.G., Griffith L., Torchilin V.P., Jain R.K. Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment. // Proc. Natl. Acad. Sci. USA. 1998. -V.95. — P.4607−4612.
- Alexis F., Rhee J.W., Richie J.P., Radovic-Moreno A.F., Langer R., Farokhzad O.C. New frontiers in nanotechnology for cancer treatment. // Urol Oncol. 2008. — V.26, Nol. — P.74−85.
- Vijayaraghavalu S., Raghavan D., Labhasetwar V. Nanoparticles for delivery of chemotherapeutic agents to tumors. // Curr. Opin. Investig. Drugs. 2007. — V.8, No6. — P.477−484.
- Moghimi S.M. Recent developments in polymeric nanoparticle engineering and their applications in experimental and clinical oncology. // Anticancer Agents Med. Chem. 2006. — V.6, No6. -P.553−561.
- Chiannilkulchai N., Driouich Z, Benoit J.P., Parodi A.L., Couvreur P. Doxorubicin-loaded nanoparticles: increased efficiency in murine hepatic metastases. // Sel. Cancer Ther. 1989. — V.5. -P.l-11.
- Leslie E.M., Deeley R.G., Cole S.P. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense.// Toxicol. Appl. Pharmacol. 2005. — V. 204, No3. — P.216−237.
- Vauthier C, Dubernet C, Chauvierre C, Brigger I, Couvreur P. Drug delivery to resistant tumors: the potential of poly (alkyl cyanoacrylate) nanoparticles. // J. Control. Release.-2003. V.93, No2.-P.151−160.
- Soma C.E., Dubernet C., Bentolila D., Benita S., Couvreur P. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. // Biomaterials. 2000. — V.21. — P. 1−7.
- Nobs L., Buchegger F., Gurny R., Allemann E. Current methods for attaching targeting ligands to liposomes and nanoparticles. // J. Pharm. Sci. 2004. -V.93.-P. 1980−1992.
- Olivier J.C. Drug transport to brain with targeted nanoparticles. // NeuroRx. -2005. V.2, Nol. — P. 108−119.
- Xu Z., Gu W., Huang J., Sui H., Zhou Z., Yang Y., Yan Z" Li Y. In vitro and in vivo evaluation of actively targetable nanoparticles for paclitaxel delivery. // Int. J. Pharm. -2005. V.288. — P. 361−368.
- Sahoo S.K., Ma. W., Labhasetwar V. Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. // Int. J. Cancer. 2004. — V. 112. — P.335−340.
- Sudimack J., Lee R.J. Targeted drug delivery via the folate receptor. // Drug Delivery Rev. 2000. — V.41. — P. 147−162.
- Zhang Z., Huey Lee S., Feng S.S. Folate-decorated poly (lactide-co-glycolide)-vitamin E TPGS nanoparticles for targeted drug delivery. // Biomaterials. 2007. — V.28, No 10. — P. 1889−1899.
- Stevens P.J., Sekido M., Lee R.J. A folate receptor-targeted lipid nanoparticle formulation for a lipophilic paclitaxel prodrug. // Pharm. Res. 2004. — V.21. — P.2153−2157.
- Hood J.D., Bednarski M., Frausto R., Guccione S., Reisfeld R.A., Xiang R, Cheresh D.A. Tumor regression by targeted gene delivery to the neovasculature. // Science. 2002. — V.296. — P.2404−2407.
- Murphy E.A., Majeti B.K., Barnes L.A., Makale M., Weis S.M., Lutu-Fuga K., Wrasidlo W., Cheresh D.A. Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. // Proc. Natl. Acad. Sci. USA. 2008. -V.105, No27. — P.9343−9348.
- Silverstein S.C., Kabbash C. Penetration, retention, intracellular localization, and antimicrobial activity of antibiotics within phagocytes. // Curr. Opin. Hematol. 1994. — V.l. — P.85−91.
- Carryn S., Chanteux H., Serai C., Mingeot-Leclercq M.P., Van Bambeke F., Tulkens P.M. Intracellular pharmacodynamics of antibiotics. // Infect. Dis. Clin. North Am. 2003. — V. l7, No3. — P.615−634.
- Couvreur P., Fattal E., Andremont A. Liposomes and nanoparticles in the treatment of intracellular bacterial infections. // Pharm. Res. 1991. — V.8, No9. — P.1079−1086.
- Fattal E., Youssef M., Couvreur P., Andremont A. Treatment of experimental salmonellosis in mice with ampicillin-bound nanoparticles. // Antimicrob. Agents Chemother. 1989. -V.33. P. 1540−1543.
- Fawaz F., Bonini F., Maugein J., Lagueny A.M. Ciprofloxacin-loaded polyisobutylcyanoaciylate nanoparticles: pharmacokinetics and in vitro antimicrobial activity. // Int. J. Pharm. 1998. — V. 168. — P.255−259.
- Gonzalez-Martin G., Merino I., Rodriguez-Cabezas M.N. Characterization and trypanocidal activity of nifurtimox-containing and empty nanoparticles of polyethylcyanoacrylates. // Pharm. Pharmacol. 1998. — V.50. — P.29−35.
- Pandey R., Zahoor A., Sharma S., Khuller G.K. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. // Tuberculosis. 2003. — V.83. — P.373−378.
- Kreuter J. Liposomes and nanoparticles as vehicles for antibiotics. // Infection. 1991. — V.19, Suppl 4. — S.224−228.
- Gelperina S., Kisich K., Iseman M.D., Heifets L. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. // Am. J. Respir. Crit. Care Med. 2005. — V. l72, Nol2. — P.1487−1490.
- Gelperina S. Brain delivery by nanoparticles. in Gupta R.B., Kompella U.B. (Eds.), Nanoparticle Technology for Drug Delivery. // Taylor and Francis. -New York, U.S.A. 2006. — P. 273−318.
- Gelperina S. Nanocarriers and drug delivery. In: Regional Cancer Chemotherapy. Schlag P.M., Stein U. (Eds.) // Humana Press. USA. — 2007. -P. 163−180.
- Гельперина С.Э., Швец В. И. Системы доставки лекарственных веществ на основе полимерных наночастиц. //Биотехнология. 2009. — Т.З. — С. 8−23.
- Misra A., Ganesh A., Shahiwala A., Shah S.P. Drug delivery to the central nervous system: a review. // J. Pharm. Pharmaceut. Sci. 2003. — V.6, No2. -P.252−273. URL http://www.ualberta.ca/~csps
- Begley D.J., Brightman M.W. Structural and Functional Aspects of the Blood-Brain Barrier. In: Prokai L., Prokai-Tatrai K. (Eds). Progress in Drug Research. V.61. // Birkhauser Verlag. — Basel (Switzerland). — 2003. — P.39−78.
- Pardridge W.M. CNS drug design based on principles of blood-barrier transport. // J. Neurochem. 1998. — V.70. — P.1781−1792.
- Tsuji A., Tamai I. Carrier-mediated or specialized transport of drugs across the blood-brain barrier. // Adv. Drug Delivery Rev. 1999. — V.36. — P.277−290.
- Groothuis D.R. The blood-brain and blood-tumor barriers: A review of strategies for increasing drug delivery. // Neuro-Oncology. 2000. — V.2. — P. 45−59.
- Pardridge W.M. Non-invasive drug delivery to the human brain using endogeneous blood-brain barrier systems. // PSTT. 1999. — V.2. — P.49−59.
- Huwyler J., Wu D., Pardridge W.P. Brain drug delivery of small molecules using immunoliposomes. // Proc. Natl. Acad. Sci. USA. 1996. — V.93. — P. 14 164−14 169.
- Kreuter J., Alyautdin R.N., Kharkevich D.A., Ivanov A.A. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). // Brain Res. 1995. — V.674. — P. 171−174.
- Alyautdin R., Gothier D., Petrov V., Kharkevich D., Kreuter J. Analgesic activity of the hexapeptide dalargin adsorbed on the surface of Ps 80-coated poly (butyl cyanoaciylate) nanoparticles. // Eur. J. Pharm. Biopharm. 1995. -V.41. — P.44−48.
- Alyautdin R.N., Petrov V.E., Langer K., Berthold A., Kharkevich D.A., Kreuter J. Delivery of loperamide across the blood-brain barrier with Ps80-coated polybutylcyanoacrylate nanoparticles. // Pharm. Res. 1997. — V.14. -P.325−328.
- Басел A.A., Петров B.E., Балабаньян В. Ю., Гельперина С. Э., Трофимов С. С., Воронина Т. А., Аляутдин Р. Н. Транспорт прозерина в головной мозг при помощи поли(бутил)цианоакрилатных наночастиц, покрытых полисорбатом. // Рос. Мед. Ж. 2006. — № 4. — С. 28−32.
- Grossman S.A., Batara J.F. Current management of glioblastoma multiforme. // Semin. Oncol. 2004. — V.31, No5. — P.635−644.
- Stupp R, van den Bent M.J., Hegi M.E. Optimal role of temozolomide in the treatment of malignant gliomas. // Curr. Neurol. Neurosci. Rep. 2005. — V.5, No3. — P.198−206.
- Fleming A.B., Saltzman W.M. Pharmacokinetics of the carmustine implant. // Clin. Pharmacokinet. 2002. — V.41, No6. — P.403−419.
- Kaajik P., Troost D., de Boer O.J. Daunorubicin and doxorubicin but not BCNU have deleterious effects on organotypic multicellular spheroids of gliomas. // Br. J. Cancer. 1996. — V.74. — P. 187−193.
- Stan A.C., Casares S., Radu D. Walter GF, Brumeanu TD. Doxorubicin-induced death in highly invasive human gliomas. // Anticancer Res. 1999. -V.19, 2A. — P. 941−950.
- Vauthier C., Dubernet C., Fattal E., Pinto-Alphandary H., Couvreur P. Poly (alkylcyanoacrylates) as biodegradable materials for biomedical applications. // Adv. Drug Deliv. Rev. 2003. — V.55, No4. — P.519−548.
- Gulyaev A.E., Gelperina S.E., Skidan I.N., Antropov A.S., Kivman G.Ya., Kreuter J. Significant transport of doxorubicin into the brain with Ps 80-coated nanoparticles. // Pharm. Res. 1999. — V.16. — 1564−1569.
- Bootz A., Russ Т., Gores F., Karas М., Kreuter J. Molecular weights of poly (butyl cyanoacrylate) nanoparticles determined by mass spectrometiy and size exclusion chromatography. // Eur J. Pharm. Biopharm. 2005. — V.60, No3. -P.391−399.
- Rolland A. Clinical pharmacokinetics in hepatoma patients after a single intravenous injection of free or nanoparticle-bound anthracyclines. // Int. J. Pharm. 1989. V.54. — P.' 113−121.
- Danesi R., Fogli S., Gennari A., Conte P., Del Tacca M., Pharmacokinetic-pharmacodynamic relationships of the anthracycline anticancer drugs. // Clin. Pharmacokinet. 2002. — V.41. — P.431−444.
- Schlageter K.E., Molnar P., Lapin G.D., Groothuis D.R. Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties. // Micro vase. Res. 1999. V.58. — P.312−328.
- Vajkoczy P., Menger M.D. Vascular microenvironment in gliomas. // Cancer Treat Res. 2004. — V. 117. — P.249−262.
- Яблоновекая Л.Я., Спрышкова H.A. Морфологическая и биологическая характеристика экспериментальных опухолей мозжечка крыс. // Арх. Патол. 1971. — Т. ЗЗ, № 2. — С. 50−53.
- Смирнова З.С., Герасимова Г. К., Родионова Ю. В. и др. Экспериментальные опухоли мозга в системе доклинического изучения новых противоопухолевых препаратов. // Материалы 5 Всероссийского съезда онкологов. Казань. — 4−7 октября 2000. — С. 214−217.
- Troster S.D., Muller U., Kreuter J. Modification of the body distribution of poly (methyl methacrylate) nanoparticles in rats by coating them with surfactants. // Int. J. Pharm. 1990. — V.61. — P. 85−100.
- Borchardt G., Kreuter J. Interaction of serum components with poly (methylmethacrylate) nanoparticles and the resulting body distribution after intravenous injection in rats. // J. Drug Target. 1993. — V. l, Nol. -P.15−19.
- Labarre D., Vauthier C., Chauvierre C., Petri В., Muller R., Chehimi M.M. Interactions of blood proteins with poly (isobutylcyanoacrylate) nanoparticles decorated with a polysaccharide brush. // Biomaterials. 2005. — V.26, No24. — P.5075−5084.
- Wilkins D.J., Myers P.A. Studies on the relationship between the electrophoretic properties and their blood clearance and organ distribution in the rat. // Brit. J. Exp. Pathol. 1966. — V.47. — P.568 — 576.
- Ambruosi A., Yamamoto H., Kreuter J. Body distribution of polysorbate-80 and doxorubicin-loaded 14C. poly (butyl cyanoacrylate) nanoparticles after i.v. administration in rats. // J. Drug Target. 2005. — V.13, NolO. — P.535−542.
- Л Y., Powers S.K., Brown J.T., Miner R. Characterization of the tumor invasion area in the rat intracerebral glioma. // J. Neurooncol. 1996. — V.30, No3. — P.189−197.
- Moos Т., Molgard К. Cerebrovascular permeability to azo dyes and plasma proteins. // Neuropath. Appl. Neurobiol. 1993. — V. 19. — P. 120−127.
- Lemarchand С., Gref R., Couvreur P. Polysaccharide-decorated nanoparticles. // Eur. J. Pharm. Biopharm. 2004. — V.58. — P.327−341.
- Kante В., Couvreur P., Dubois-Krack G., De Meester C., Guiot P., Roland M., Mercier M., Speiser P. Toxicity of polyalkylcyanoacrylate nanoparticles I: Free nanoparticles. // J. Pharm. Sci. 1982. — V.71. — P.786−790.
- Kreuter J., Gelperina S. Use of nanoparticles for cerebral cancer. Tumori. -2008. V.94, No2. — P.271−277.
- Hekmatara Т., Gelperina S., Vogel V., Yang Sh.-R., Kreuter J. Encapsulation of water-insoluble drugs in poly (butyl cyanoacrylate) nanoparticles. // J. Nanosci. Nanotechnol. 2009. — V.9. — P.5091−5098.
- Zhou R., Mazurchuk R., Straubinger R.M. Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model. // Cancer Res. 2002. — V.62. — P.2561−2566.
- Straubinger R.M., Arnold R.D., Zhou R., Mazurchuk R., Slack J.E. Antivascular and antitumor activities of liposome-associated drugs. // Anticancer Res. 2004. — V.24. — P.397−404.
- Гельперина С.Э., Смирнова 3.C., Халанский A.C., Скидан И. Н, Северин С. Е., Кройтер Й. Исследование наносомальной лекарственной формы доксорубицина. // Рос. биотерапевт, ж. 2004. — Т.З. — С.56−64.
- Pereverzeva Е., Treschalin I., Bodyagin D., Maksimenko О., Kreuter J., Gelperina S. Intravenous tolerance of a nanoparticle-based formulation of doxorubicin in healthy rats. // Toxicol. Lett. 2008. — V.178, Nol. — P. 9−19.
- Stojiljkovic M.P., Zhang D., Lopes H.F., Lee C.G., Goodfriend T.L., Egan B.M. Hemodynamic effects of lipids in humans. // Am. J. Physiol. Regul. Integr. Comp. Physiol. 2001. — V.280, No 6. — R1674-R1679.
- Szebeni J. Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents. // Crit. Rev. Ther. Drug Carrier Syst. 2001. — V. 18, No6. — P.567−606.
- Mazue G., Iatropoulos M., Imondi A., Castellino S., Brughera M., Podesta A., Delia Torre P., Moneta D. Anthracyclines: a review of general and special toxicity studies. // Int. J. Oncol. 1995. — V.7. — 713−726.
- Zucchi R, Danesi R. Cardiac toxicity of antineoplastic anthracyclines. // Curr. Med. Chem. Anti-Cancer Agents. — 2003. — V.3. — P.151−171.
- Olivier J.C., Fenart L., Chauvet R., Pariat C., Cecchelli R" Couet W. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. // Pharm. Res. -1999. V. 16. — P. 1836−1842.
- Simeonova M., Chorbadjiev K., Antcheva M. Study of the effect of polybutylcyanoacrylate nanoparticles and their metabolites on the primary immune response in mice to sheep red blood cells. // Biomaterials. 1998. — -19, No23.-P.2187−21 893.
- Couvreur P., Kante В., Grislain L., Roland M., Speiser P. Toxicity of polyalkylcyanoacrylate nanoparticles II: Doxorubicin-loaded nanoparticles. // J. Pharm. Sei. 1982. — V.71. -P.790−792.
- Borchardt G., Audus K.L., Shi F., Kreuter J. Uptake of surfactant-coated poly (methyl methacry late)-nanoparticles by bovine brain microvessel endothelial cell monolayers. // Int. J. Pharm. 1994. — V. l 10. — P.29−35.
- Luck M. Plasmaproteinadsorption als moglicher Schlusselfaktor fur eine kontrollierte Arzneistoffapplikation mit partikularen Tragern. // Ph.D. Thesis. Freie Universitat Berlin. — 1997. — P. 13 7−154.
- Alyautdin R., Reichel A., Lobenberg R., Ramge P., Kreuter J., Begley D. Interaction of poly (butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro.// J. Drug Targeting. 2001. — V.9. — P.209−221.
- Kreuter J., Shamenkov D., Petrov V., Ramge P., Cychutek K., Koch-Brandt C., Alyautdin R. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. //J. Drug Targeting. 2002. — V.10. -P.317−326.
- Panzenboeck U., Balazs Z., Sovic A., Hrzenjak A., Levak-Frank S., Wintersperger A., Malle E., Sattler W. ABCA1 and scavenger receptor class
- B, type I, are modulators of reverse sterol transport at an in vitro blood-brain barrier constituted of porcine brain capillary endothelial cells. //J. Biol. Chem.- 2002. V.277. — P.42 781−42 789.
- Hu Y.-P., Jarillon S., Dubernet C., Couvreur P., Robert J. On the mechanism of action of doxorubicin encapsulation in nanospheres for the reversal of multidrug resistance. // Cancer Chemother. Pharmacol. 1996. — V.37. -P.556−650.
- Sommerfeld P., Schroeder U., Sabel B. Sterilization of unloaded polybutylcyanoacrylate nanoparticles. // Int. J. Pharm. 1998. — V. 164. -P.113−118.
- Сборник нормативно-методических документов, регламентирующих радиационную стерилизацию медицинских материалов и изделий. // Москва. 1980. — Методики 1.5.2., 1.5.3.
- El-Egakey М.А., Bentele V., Kreuter J. Molecular weights of polycyanoacrylate nanoparticles. //Int. J. Pharm. 1983. — V.13. — P.349 -352.
- Милинчук В.К., Клиншпонт Э. Р., Тупиков В. И. Основы радиационной стойкости органических материалов. // Энергоатомиздат. Москва. -1994. — С.142−147.
- Lenaerts V., Couvreur P., Christiaens-Leyh D., Joiris E., Roland M., Rollman В., Speiser P. Degradation of poly (isobutyl cyanoacrylate) nanoparticles. // Biomaterials. 1984. — V.5, No2. — P.65−68.
- Muller R.H., Lherm C, Herboit J., Couvreur P. In vitro model for the degradation of alkylcyanoacrylate nanoparticles. // Biomaterials. 1990. -V. 11, No8. — P.590−595.
- Lherm C., Muller R., Puisieux F., Couvreur P. II. Cytotoxicity of cyanoacrylate nanoparticles with different alkyl chain length. // Int. J. Pharm. 1992. -V.84.- P. 13−22.
- Mohamed F., van der Walle C.F. Engineering biodegradable polyester particles with specific drug targeting and drug release properties. // J. Pharm. Sei. 2008. — V.97, Nol. — P.71−87.
- Langer К., Seegmueller Е., Zimmer А., Kreuter J. Characterization of polybutylcyanoacrylate nanoparticles. I. Quantification of PBCA polymer and dextrans. // Int. J. Pharm. 1994. — V. l 10. — P.21−27.
- Agrawal S., Panchagnula R. In vitro analysis of rifampicin and its effect on quality control tests of rifampicin containing dosage forms. // Pharmazie. -2004. V.59, NolO. — P.775−781.
- Ueda M., Kreuter J. Optimization of the preparation of loperamide-loaded poly (L-lactide) nanoparticles by high pressure emulsification-solvent evaporation. // J. Microencapsul. 1997. — V.14, No5. — P.593−605.
- Lamprecht A., Ubrich N., Perez M.H., Lehr C.-M., Hoffman M., Maincent P. Influences of process parameters on nanoparticle preparation performed by a double emulsion pressure homogenization technique. // Int. J. Pharm. -2000.-V.196.-P. 177−182.
- Гельперина С.Э., Максименко O.O., Ванчугова Л. В., Шипуло Е. В., Шандрюк Г. А., Бондаренко Г. Н., Швец В. И. Влияние технологических параметров на физико-химические свойства полилактидных наночастиц, содержащих рифампицин. // Хим.-фарм. ж, в печати
- Marzipans Т.Т., Sharda N., Singh S. Atypical Log D profile of rifampicin. // Indian J. Pharm. Sei. serial online. 2007. — V.69. — P. l97−201.
- Bain D.F., Munday D.L., Cox P. Evaluation of biodegradable rifampicin-bearing microsphere formulations using a stability-indicating highperformance liquid chromatographic assay. // J. Eur. J. Pharm. Sci. 1998. -V.7, No 1. — P.57−65.
- Siepmann J., Faisant N., Akiki J., Richard J., Benoit J.P. Effect of the size of biodegradable microparticles on drug release: experiment and theory. // J. Control. Release. 2004. — V.96, Nol. — P. 123−134.
- Faisant N., Siepmann J., Benoit J.P. PLGA-based microparticles: elucidation of mechanisms and a new, simple mathematical model quantifying drug release. // Eur. J. Pharm. Sci. 2002. — V.5, No4. — P.355−366.
- Vandervoort J., Ludwig A. Biocompatible stabilizers in the preparation of PLGA nanoparticles: a factorial design study. // Int. J. Pharm. 2002. -V.238. — P.77−92.
- Birnbaum D.T., Kosmala J.D., Brannon-Peppas L. Optimization of preparation techniques for poly (lactic acid-co-glycolic acid) nanoparticles. // J. Nanoparticle Res. 2000. — V.2. — P. 173−181.
- Wang X.Y., Ishida Т., Ichihara M., Kiwada H. Influence of the physicochemical properties of liposomes on the accelerated blood clearance phenomenon in rats. // J. Control. Release. 2005. — V. 104, Nol. — P. 91−102.
- Ishida Т., Harashima H., Kiwada H. Liposome clearance. // Biosci. Rep. -2002. V.22, No2. — P .197−224.
- Скидан И.Н., Гельперина С. Э., Северин C.E., Гуляев А. Е. Повышение антибактериальной активности рифампицина в отношении внутриклеточных инфекций с помощью биодеградируемых наночастиц. // Антибиот. Химиотер. 2003. — Т.48, № 1. — С.23−26.
- Гельперина С.Э., Гуляев А. Е., Иванов А. А., Пальцев М. А., Северин Е. С., Северин С. Е., Скидан И. Н. Композиция для лечения легочных инфекций. // Патент РФ № 2 185 818, приоритет 10.07.2001.
- Anisimova Y., Gelperina S., Peloquin С., Heifets L. Nanoparticles as antituberculosis drug carriers: effect on activity against Mycobacterium tuberculosis in human monocyte-derived macrophages. // J. Nanoparticle Res. 2000. V.2. -P.165−171.
- Heifets L. MIC as a quantitative measurement of the susceptibility of Mycobacterium avium strains to seven antituberculosis drugs. // Antimicrob Agents Chemother. 1988. — V.32, No8! — P. l 131−1136.
- Shoen C.M., DeStefano M.S., Sklaney M.R., Monica B.J., Slee A.M., Cynamon M.H. Short-course treatment regimen to identify potential antituberculous agents in a murine model of tuberculosis. // J AC. 2004. -V.53.-P.641−645.
- Burman W.J., Gallicano K., Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. // Clin. Pharmacokinet. -2001. V.40, No5. — P.327−341.
- Schultz M.J., van der Poll T. Animal and human models for sepsis. // Ann. Med. 2002. — V.34. — P.573−581.
- Calandra T. Pathogenesis of septic shock: implication for prevention and treatment. // J. Chemotherapy. 2001. — V. 13. — P. l73−180.
- Fresta M., Puglisi G. Association of netilmicin sulphate to poly (alkylcyanoacrylate) nanoparticles: factors influencing particle delivery behaviour. // Drag Development Industr. Pharm. 1994. — V.20, No 14. -P.2227−2243.
- Beutler В., Milsark I.W., Cerami A.C. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. // Science. 1985. — V.229. -P.869−871.
- Dhillon J., Mitchison D.A. Activity and penetration of antituberculosis drugs in mouse peritoneal macrophages infected with Micobacterium microti OV254. // Antimicrob. Agents Chemother. 1989. — V.33, No8. — P. 12 551 259.
- Maincent P., Thouvenot P., Amicabile C., Hoffman M., Kreuter J., Couvreur P., Devissaguet J.P. Lymphatic targeting of polymeric nanoparticles after intraperitoneal administration in rats. // Pharm. Res. 1992. — V.9, No 12. -P.1534−1539.
- Перёльман М.И., Соколова Г. Б., Можохина Г. Н., Лазарева Я. В., Стрекачев А. Ю., Елистратова Н. А. Применение моксифлоксацина для оптимизации комплексной терапии туберкулеза. // Антибиот. химиотер.- 2004. Т.49, № 6. — С.20−24.
- Ballow С., Lettieri J., Agarwal V., Liu P., Stass H., Sullivan J. Absolute bioavailability of moxifloxacin. // Clin. Ther. 1999. — V.21. — C.513−522.
- Stass H., Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. // J. Antimicrob. Chemother. -1999. V.43, Suppl B. — P.83−90.
- Douglas S.J., Ilium L., Davis S.S., Kreuter J. Particle size and size distribution if poly (butyl-2-cyanoacrylate) nanoparticles. // J. Colloid Interface Sci. 1984. — V. 101, No 1. — P. 149−175.
- Fawaz F., Guyot M., Lagueny A.M., Devissageut J.Ph. Ciprofloxacin-loaded polyisobutylcyanoacrylate nanoparticles: preparation and characterization. // Int. J. Pharm. 1997. — V.154. — P. 191−203.
- Lherm C., Mueller R., Puisieux F., Couvreur P. II. Cytotoxicity of cyanoacrylate nanoparticles with different alkyl chain length. // Int. J. Pharm.- 1992.-V.84.-P. 13−22.
- Page-Clisson M.E. Pinto-Alphandary H., Ourevitch M., Andremont A., Couvreur P. Development of ciprofloxacin-loaded nanoparticles: physicochemical study of the drug carrier. //J. Control. Release. 1998. -V.56. — P.23−32.
- Hall, I.H., Schwab, U.E., Ward, E.S., Ives, T. Disposition and intracellular levels of moxifloxacin in human THP-l monocytes in unstimulated and stimulated conditions. // Int. J. Antimicrob. Agents. 2003. — V.22. — P. 579−587.
- Clemens D.L., Lee B.Y., Horwitz M.A. The Mycobacterium tuberculosis phagosome in human macrophages is isolated from the host cell cytoplasm. // Infect. Immun. 2002. — V.70. — P.5800−5807.
- Северин E.C., Свешников П. Г., Гельперина С. Э., Максименко О. О., Шипуло Е. В., Ванчугова JI.B. Антибактериальное средство для лечения внутриклеточных инфекций. // Патент РФ № 2 308 970, приоритет 10.03.2006
- Лабораторные животные (Положение и руководство), под ред. Н. Н. Каркищенко, М. // Межакадемическое издательство «ВПК». 2003. -С.138.
- Harnisch S., Muller R.H. Plasma protein adsorption patterns on emulsions for parenteral administration: establishment of a protocol for two-dimensional polyacrylamide electrophoresis. // Electrophoresis. 1998. — V.19. — P.349−354.
- Методика определения инициальной контаминации продукции, стерилизуемой радиационным способом. Утверждена МЗ 11.02.82, per. № 2535−82.
- Методические указания по использованию непрямого метода определения радиорезистентности производственной микрофлоры на предприятии, выпускающем радиационно-стерилизуемую продукцию. Утверждены МЗ 10.10.90, per. № 15−6/37.
- Першин Г. Н. Методы экспериментальной химиотерапии. Практическое руководство. // 1971. -«Медицина». Москва.